V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220021521 | 220018014 | 1.83 | 88.5 | Curative (C) | 2016-10-24 | 2016-10-24 | PONATINIB | N | N | 220032635 | METHOTREXATE |
| 220021522 | 220008669 | 1.83 | 74 | Curative (C) | 2014-03-23 | 2015-03-04 | Alemtuzumab cond (RI ALLO CAMP100) | null | null | 220032681 | ALEMTUZUMAB |
| 220021524 | 220008695 | 1.67 | 67.1 | Palliative (P) | 2018-03-08 | 2018-03-08 | Mitoxantrone | N | N | 220032728 | MITOXANTRONE |
| 220021525 | 220008706 | 1.69 | 89.4 | Adjuvant (A) | null | 2015-05-24 | Clofarabine + Cytarabine | 02 | N | 220032770 | UKALL2014 |
| 220021526 | 220014686 | 1.57 | 54.4 | Curative (C) | 2017-05-09 | 2017-05-28 | IDARUBICIN | null | null | 220032784 | IDARUBICIN |
| 220021527 | 220008719 | 1.59 | 60.2 | Palliative (P) | 2017-08-20 | 2017-08-20 | Carboplatin + Etoposide iv&po | null | null | 220032794 | CARBOPLATIN + ETOPOSIDE |
| 220021528 | 220008732 | 1.76 | 87.7 | Adjuvant (A) | 2016-04-14 | 2016-04-14 | ALEMTUZUMAB + BUSULFAN + FLUDARABINE | 02 | N | 220032856 | PONATINIB |
| 220021529 | 220014703 | 1.7 | 84.4 | Disease modification (D) | 2018-09-08 | 2018-09-20 | Cytarabine intrathecal | 02 | N | 220032908 | CYTARABINE INTRATHECAL |
| 220021530 | 220008769 | 1.69 | null | Curative (C) | 2016-10-31 | 2016-11-01 | Cytarabine intrathecal | N | N | 220032973 | CYTARABINE INTRATHECAL |
| 220021532 | 220008828 | 1.76 | null | Palliative (P) | 2018-01-06 | 2018-01-11 | MYELOMA XI TRIAL | N | null | 220033156 | FLA |
| 220021533 | 220018057 | 1.77 | null | Curative (C) | 2017-01-24 | 2017-06-08 | VINCRISTINE | N | N | 220033249 | MITOXANTRONE + TRETINOIN |
| 220021534 | 220008846 | 1.9 | 92.7 | Curative (C) | 2014-06-24 | 2017-02-27 | Capecitabine | N | N | 220033250 | CHOP R |
| 220021535 | 220008869 | 1.82 | 64.1 | Palliative (P) | null | 2015-03-25 | MidAC | 02 | N | 220033375 | IPM |
| 220021536 | 220018065 | 1.91 | null | Disease modification (D) | 2016-12-15 | 2016-12-16 | FLA | N | null | 220033397 | CISPLATIN + RT |
| 220021537 | 220008874 | 1.86 | 94 | Palliative (P) | 2016-01-30 | 2016-02-03 | IPM | N | N | 220033438 | MA |
| 220021538 | 220014759 | 1.78 | 76.3 | Curative (C) | 2019-01-17 | 2019-01-17 | FIGARO TRIAL | N | N | 220033449 | BUSULPHAN + CYCLO |
| 220021539 | 220008886 | 1.87 | 17.1 | Not known (9) | 2018-01-07 | 2019-04-29 | LIPOSOMAL CYTARABINE | 01 | null | 220033473 | ARSENIC TRIOXIDE + ATRA |
| 220021540 | 220008899 | null | 104.499 | Curative (C) | 2016-03-22 | 2016-09-09 | FLUOROURACIL | 02 | N | 220033508 | CYTARABINE IT + METHOTREXATE |
| 220021541 | 220014767 | 1.67 | 63.5 | Curative (C) | 2018-03-17 | 2018-03-20 | CETUXIMAB | N | N | 220033515 | FLUOROURACIL |
| 220021542 | 220014770 | 1.86 | null | Curative (C) | 2016-08-02 | 2016-09-02 | Ipilimumab | 01 | N | 220033551 | ATG + BUSULFAN + CYCLOPHOSPHAMIDE |
| 220021543 | 220014774 | 1.76 | 78.2 | Curative (C) | 2016-02-27 | 2016-03-05 | Etoposide oral | N | N | 220033571 | LIPOSOMAL CYTARABINE |
| 220021544 | 220008936 | 1.66 | 84 | Curative (C) | 2017-03-15 | 2017-04-03 | VINORELBINE | N | N | 220033681 | CLOFARABINE + CYCLO + CYTARABINE + ETOP |
| 220021545 | 220008939 | null | 70 | Curative (C) | 2016-03-13 | 2016-03-13 | ALL UKALL2003 TRIAL | 2 | null | 220033703 | ARSENIC TRIOXIDE + ATRA |
| 220021546 | 220008943 | 1.67 | null | null | 2015-01-14 | 2015-01-14 | R GCVP | N | null | 220033717 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 220021547 | 220008959 | 1.62 | 50.1 | Disease modification (D) | null | 2017-10-12 | Cisplatin 7 day | N | N | 220033807 | ARSENIC TRIOXIDE + ATRA |
| 220021548 | 220014794 | 1.49 | 73 | Curative (C) | 2018-07-19 | 2018-07-31 | Arsenic Trioxide (Induction Week) | 2 | N | 220033808 | CAPECITABINE + GEMCITABINE |
| 220021549 | 220021584 | 1.73 | 67.6 | Curative (C) | 2016-04-11 | 2016-04-11 | Everolimus 10mg | N | N | 220033832 | CAPECITABINE |
| 220021550 | 220009011 | 1.96 | 94.2 | Disease modification (D) | 2016-11-30 | 2016-12-02 | Cisplatin + Vinorelbine (IV) | 02 | N | 220033965 | ARSENIC TRIOXIDE + ATRA |
| 220021551 | 220009022 | 1.57 | 89 | Curative (C) | 2013-11-16 | 2014-11-04 | INTERFERON | N | N | 220033988 | SORAFENIB |
| 220021552 | 220009027 | 1.75 | 0 | Curative (C) | 2018-10-16 | 2018-10-16 | CARFILZOMIB | N | N | 220033997 | ARSENIC TRIOXIDE + ATRA |
| 220021553 | 220009033 | 0 | null | Curative (C) | 2017-05-27 | 2017-05-28 | BUSULFAN + MELPHALAN | 2 | N | 220034022 | BUSULPHAN + CYCLO |
| 220021554 | 220009049 | null | null | null | 2015-04-18 | 2015-07-16 | Alemtuzumab + Cyclophos TBI Allo | N | N | 220034079 | GANETESPIB |
| 220021555 | 220009052 | 1.55 | 48 | Curative (C) | 2015-02-19 | 2015-03-03 | CETUXIMAB | N | N | 220034081 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE |
| 220021556 | 220009062 | 1.6 | 57.1 | null | 2017-01-30 | 2017-02-16 | Arsenic Triox + Tretinoin Ind W1-4 | N | null | 220034115 | TEMOZOLOMIDE |
| 220021557 | 220009068 | null | 86.5 | Curative (C) | 2014-12-10 | 2014-12-11 | Cytarabine+Methotrexate Intrathecal | Y | null | 220034117 | IGEV R |
| 220021558 | 220009086 | null | 29.4 | Curative (C) | 2015-06-21 | 2016-10-04 | Bevacizumab+Carbo+Pacliaxel | null | N | 220034194 | SORAFENIB |
| 220021559 | 220009105 | 1.75 | 94 | Curative (C) | 2017-09-07 | 2018-01-11 | CETUXIMAB + IRINOTECAN + MDG | N | N | 220034277 | EOX |
| 220021560 | 220019941 | 1.68 | 58.91 | Palliative (P) | 2016-05-08 | 2016-06-12 | MidAC | N | null | 220034302 | CYTARABINE + FLUDARABINE |
| 220021561 | 220014863 | 1.84 | 80.3 | Disease modification (D) | 2014-11-11 | 2014-11-14 | MELPHALAN | null | Y | 220034334 | ABVD |
| 220021562 | 220009134 | null | 62.7 | Curative (C) | 2017-09-12 | 2017-09-25 | Capecitabine (14 day) + Irinotecan | N | N | 220034423 | TRASTUZUMAB |
| 220021563 | 220009137 | null | 76 | Curative (C) | 2018-01-29 | 2018-12-23 | Busulfan + Cyclophos Conditioning | N | N | 220034424 | CYCLOPHOSPHAMIDE + FLUDARABINE + THIOTEPA |
| 220021564 | 220014879 | null | null | Curative (C) | 2015-04-15 | 2015-04-24 | CYTARABINE + Hydrocortisone + Hydrocortisone + METHOTREXATE | N | null | 220034495 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 220021565 | 220009185 | null | 73 | Disease modification (D) | 2016-07-06 | 2016-07-12 | PEMBROLIZUMAB | null | null | 220034571 | FLUDARABINE |
| 220021566 | 220009195 | 1.8 | 101.8 | Palliative (P) | 2014-12-06 | 2016-07-21 | DABRAFENIB + TRAMETINIB | 2 | N | 220034611 | TRASTUZUMAB |
| 220021567 | 220009208 | 1.77 | 80 | Curative (C) | 2014-04-05 | 2014-04-05 | Arsenic Triox + Tretinoin Ind W1-4 | 2 | N | 220034670 | DAUNORUBICIN + VNCRISTINE |
| 220021568 | 220009215 | null | null | Not known (9) | null | 2017-12-14 | Cytarabine+Methotrexate Intrathecal | null | null | 220034678 | ARSENIC TRIOXIDE + ATRA |
| 220021569 | 220009220 | 1.55 | 47.6 | Curative (C) | 2016-11-11 | 2016-11-16 | Mercaptopurine | null | N | 220034690 | LENALIDOMIDE |
| 220021570 | 220009280 | 1.73 | 64.5 | Curative (C) | 2017-01-03 | 2017-01-04 | MITOXANTRONE + TRETINOIN | N | N | 220035065 | FIGARO TRIAL |
| 220021572 | 220009315 | 1.64 | 76.25 | Curative (C) | 2018-06-22 | 2018-07-07 | Cyclophosphamide High Dose | N | N | 220035189 | CETUXIMAB |
| 220021573 | 220009327 | null | 80.3 | Palliative (P) | 2019-05-30 | 2019-06-03 | CARBOPLATIN | Y | null | 220035229 | IPILIMUMAB |